The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

[1]  S. Kannan,et al.  Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Fisher,et al.  Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. , 2020, The Lancet Oncology.

[3]  N. Magné,et al.  Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[4]  M. Parmar,et al.  Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial , 2020, The Lancet.

[5]  M. Sydes,et al.  Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data , 2020, The Lancet.

[6]  P. Hurmuz,et al.  Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  M. Duma,et al.  PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. , 2020, European urology oncology.

[8]  W. R. Lee,et al.  Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. , 2020, JAMA oncology.

[9]  N. Magné,et al.  Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. , 2019, The Lancet. Oncology.

[10]  Roger Slavik,et al.  18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. , 2019, The Lancet. Oncology.

[11]  Adam P Dicker,et al.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[12]  D. Spratt.  Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[13]  Zaid A. Siddiqui,et al.  Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy , 2018, Translational andrology and urology.

[14]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[15]  M. Kattan,et al.  Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. , 2016, International journal of radiation oncology, biology, physics.

[16]  Shree Agrawal,et al.  Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Dubray,et al.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. , 2016, The Lancet. Oncology.

[18]  R. Bristow,et al.  Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy? , 2016, Clinical Cancer Research.

[19]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[20]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[21]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[22]  Issam El Naqa,et al.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[23]  C. Ménard,et al.  RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[24]  E. Messing,et al.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.

[25]  E. Horwitz,et al.  The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer , 2008, Cancer.

[26]  E. Messing,et al.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Richard K Valicenti,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[29]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[30]  J. Forman,et al.  Salvage radiation for a rising PSA following radical prostatectomy. , 2004, Urologic oncology.

[31]  S. Schild,et al.  Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. , 2003, The Journal of urology.

[32]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Boris Freidlin,et al.  A comment on futility monitoring. , 2002, Controlled clinical trials.

[34]  R. Simon,et al.  Extension of one-sided test to multiple treatment trials. , 1994, Controlled clinical trials.

[35]  R C Bruskewitz,et al.  Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[36]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[37]  M Zelen,et al.  The randomization and stratification of patients to clinical trials. , 1974, Journal of chronic diseases.

[38]  Emil Frei,et al.  Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .